NCT00152425View on ClinicalTrials.gov

Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).

PHASE3CompletedINTERVENTIONAL
Enrollment

392

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions
Crohn's Disease
Interventions
DRUG

Certolizumab Pegol (CDP870)

Sponsors

Lead Sponsor

UCB Pharma
All Listed Sponsors
lead

UCB Pharma

INDUSTRY